#United States #Dublin #earnings report #Cardinal Health #Fiscal 2026

Cardinal Health Reports Third Quarter Fiscal Year 2026 Results

On April 30, 2026, Cardinal Health (NYSE: CAH) disclosed its third quarter revenue results for the fiscal year 2026, reporting an impressive revenue figure of $60.9 billion, which translates to an 11% increase compared to the same quarter from the previous fiscal year. This significant upturn illustrates the company's robust market performance, particularly within its Pharmaceutical and Specialty Solutions segment.

Despite the revenue growth, the company's GAAP operating earnings saw a decline of 30%, dropping to $509 million. This decline is attributed to a $184 million pre-tax goodwill impairment within the Navista ION unit, reflecting a reassessment of business risk estimates.

On a more favorable note, Cardinal Health's non-GAAP operating earnings demonstrated a positive trend, rising 18% to $956 million, and its non-GAAP diluted earnings per share surged 35% to $3.17. These figures are promising indicators that the company's strategies to enhance operational efficiency are taking effect, despite the challenges faced.

Segment Highlights

Pharmaceutical and Specialty Solutions

The Pharmaceutical and Specialty Solutions segment remains a cornerstone of Cardinal Health's strength, achieving $56.1 billion in revenue, also up 11% from the previous year. This growth is largely driven by strong sales of brand and specialty pharmaceuticals among existing customers. The segment profit rose 18% to $784 million, reflecting effective management and product positioning.

Global Medical Products and Distribution

In contrast, the Global Medical Products and Distribution segment reported stable revenues of $3.1 billion, remaining flat compared to last year. However, this segment's profitability faced a setback, with profits decreasing 36% to $25 million, largely due to external factors like tariffs affecting the market dynamics.

Other Segments

In the other operating segments, Cardinal Health achieved a noteworthy 31% increase in revenue, reaching $1.7 billion. This segment, which includes at-home health solutions and new acquisitions, yielded a profit of $179 million, reflecting a 34% year-on-year growth.

Strategic Actions and Outlook

Cardinal Health's management expressed optimism regarding the company's trajectory moving forward. In light of the current performance, Cardinal Health has updated its fiscal year 2026 guidance for non-GAAP diluted EPS to a range of $10.70 to $10.80, indicating a robust 30% to 31% growth projection for the year.

In addition, the company has actively reduced its debt by finalizing a $100 million term loan payment ahead of schedule and recently completed a $250 million accelerated share repurchase, bringing the total share repurchase for FY2026 to $1.0 billion. Such movements not only illustrate Cardinal Health's commitment to improving shareholder value but also indicate its focus on maintaining a strong balance sheet amidst challenging operational landscapes.

Conclusion

Cardinal Health’s results for the third quarter in fiscal year 2026 highlight a company showing resilience in a complex market environment. Even though certain challenges, including goodwill impairments and segment-specific performance dips, have presented hurdles, the overall growth in revenue and strong non-GAAP earnings augurs well for Cardinal Health’s future endeavors. As the company continues to innovate and evolve its service offerings, it remains set to maintain its trajectory of growth and profitability in an ever-changing healthcare landscape.

For further information, interested parties can access the webcast detailing these results on Cardinal Health's Investor Relations page, where a comprehensive presentation will be available.